<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01121198</url>
  </required_header>
  <id_info>
    <org_study_id>1941-CL-0101</org_study_id>
    <nct_id>NCT01121198</nct_id>
  </id_info>
  <brief_title>A Study to Assess Safety and Tolerability of ASP1941 After Single and Repeated Administration in Healthy Subjects</brief_title>
  <official_title>ASP1941 Phase I Study —Placebo-controlled, Single-dose and Repeated-dose Oral Administration Study in Healthy Adult Male Subjects—</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Astellas Pharma Inc</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Astellas Pharma Inc</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is to assess the safety, tolerability, pharmacokinetics and pharmacodynamics of
      ASP1941 in healthy adult male subjects.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study consists of two parts. In part-1, a single oral dose of ASP1941 or placebo is
      administered to healthy adult male subjects to investigate the safety, tolerability,
      pharmacokinetics and pharmacodynamics in healthy adult males. In part-2, ASP1941 or placebo
      are is administered by a multiple dose regimen.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>December 2006</start_date>
  <completion_date type="Actual">July 2007</completion_date>
  <primary_completion_date type="Actual">July 2007</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety assessed by adverse events, vital signs, 12-lead ECG and lab-tests</measure>
    <time_frame>72 hours after drug administration</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Plasma concentration of unchanged drug measured by blood sample</measure>
    <time_frame>72 hours after drug administration</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Blood glucose level measured by blood sample</measure>
    <time_frame>72 hours after drug administration</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Urinary glucose excretion level</measure>
    <time_frame>72 hours after drug administration</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">84</enrollment>
  <condition>Healthy Volunteer</condition>
  <condition>Pharmacokinetics of ASP1941</condition>
  <arm_group>
    <arm_group_label>ASP1941 single arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>ASP1941 repeated arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>placebo single arm</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>placebo repeated arm</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ASP1941</intervention_name>
    <description>oral</description>
    <arm_group_label>ASP1941 single arm</arm_group_label>
    <arm_group_label>ASP1941 repeated arm</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>oral</description>
    <arm_group_label>placebo single arm</arm_group_label>
    <arm_group_label>placebo repeated arm</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Body weight: 50.0 kg ≤ weight &lt; 85.0 kg

          -  Body mass index:17.6 ≤ BMI &lt; 26.4

          -  Those who provided written informed consent themselves

        Exclusion Criteria:

          -  Medical history of Hepatic disease, heart disease, respiratory disease,
             gastrointestinal disease, renal disease, cerebrovascular disease, malignant tumor or
             drug allergy

          -  Those whose blood pressure, pulse rate, body temperature or 12-lead ECG are in the
             abnormal range

          -  Those whose lab-test results are in the abnormal range

          -  Those who received medical treatment within 14 days prior to the study

          -  Those who attended another clinical study or a post-marketing clinical trial within
             120 days before the study

          -  Those who have received ASP1941 before

          -  Those who have donated at least 400ml of whole blood within 90 days before the study,
             at least 200ml 30 days before the study or blood component within 14 days before the
             study

          -  Those within a fasting plasma glucose level of &lt; 70mg/dL or 110 mg/dL or with an
             HbA1C. 5.8%
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>44 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Use Central Contact</last_name>
    <role>Study Chair</role>
    <affiliation>Astellas Pharma Inc</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Kantou</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <verification_date>May 2010</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 10, 2010</study_first_submitted>
  <study_first_submitted_qc>May 10, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 12, 2010</study_first_posted>
  <last_update_submitted>May 10, 2010</last_update_submitted>
  <last_update_submitted_qc>May 10, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 12, 2010</last_update_posted>
  <responsible_party>
    <name_title>Director</name_title>
    <organization>Astellas Pharma, Inc</organization>
  </responsible_party>
  <keyword>Food effect</keyword>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

